FDA Panel Recommends Amgen’s Enbrel For Kids
By John Wolper
00:08, June 19th 2008
25 votes
Vote this story
FDA Panel Recommends Amgen’s Enbrel For Kids

A FDA panel recommended that the psoriasis drug Enbrel should be approved for the treatment of the pediatric patients who are diagnosed with moderate-to severe forms of this illness.

Enbrel, produced by Amgen, is a soluble tumor necrosis factor (TNF) receptor fusion protein that binds TNF-α. Enbrel was first approved by the FDA in 1998 for the treatment of adult rheumatoid arthritis, and is currently approved for the treatment of rheumatoid arthritis, polyarticular-course juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and adult plaque psoriasis. Currently in the US, there are no approved systemic drugs for the treatment of psoriasis in children or adolescents.

Plaque psoriasis is a chronic T-lymphocyte mediated inflammatory skin disease characterized by erythematous plaques with silvery-white scales. Psoriasis plaques are characterized by keratinocyte hyperproliferation, vascular endothelial proliferation and inflammatory cell infiltration. The most common form of psoriasis in children is plaque psoriasis.

The mainstay of treatment for most psoriasis patients regardless of age is topical therapy. Emollients are used to decrease scaling and itching, and may be sufficient in mild cases. The most commonly used treatment is topical corticosteroids.

There is no approved systemic therapy for the treatment of plaque psoriasis in the pediatric population. Systemic therapy for treating childhood psoriasis is generally reserved for the most severe plaque psoriasis recalcitrant to topical therapies. The National Center for Health Statistics of the Centers for Disease Control and

Prevention estimated in 1996 that the prevalence of the disease in children under the age of 18 was 0.32%. Of affected children, 2% of cases begin in the first two years of life and 10% are diagnosed before the age of 10 years.

Amgen has submitted to the panel the results from its Phase III study of Enbrel. The study was made on 211 patients lasting a total of 48 weeks. The study initially randomized patients to placebo or etanercept at 0.8 mg/kg weekly by subcutaneous injection for 12 weeks. All participants then received open-label etanercept for an additional 24 weeks.

Among the young patients treated with the drug for 12 weeks, 57 percent showed that at least a 75 percent improvement in disease severity scored compared with only 11 percent of those receiving a placebo.

The patients encountered mild or moderate side effects. The most common were upper tract infections, headache, nasopharyngitis, injection-site reactions, streptococcal pharyngitis, cough, vomiting and skin papilloma. There were four serious events including three infections and one ovarian cyst, which required removal. All patients recovered without permanent problems.

However, the FDA panel expressed its concerns that Enbrel, although it appears to be an effective therapy, will increase risks of malignancy and serious infections like tuberculosis.

Seven members has voted for the approval, while five expressed their disagreement. In fact, earlier this month, FDA announced it will review Enbrel, along with other several TNF blockers, because they might lead to cancer in children and young adults.

Besides Enbrel, the drugs under investigation are infliximab (Remicade, Johnson & Johnson) and adalimumab (Humira, Abbott Laboratories).



© 2007 - 2008 - eFluxMedia
Share the News:
Del.icio.us Digg Stumble Upon Facebook Newsvine Mixx
dotclear

Other News in

National Guideline Against Ear Poking

National Guideline Against Ear Poking

The American Academy of Otolaryngology - Head and Neck Surgery Foundation released a national guideline so that clinicians may recognize earwax buildup and so that they know how to deal with it....

Salmonella Outbreak Allegedly Over, Questions Are Not

Salmonella Outbreak Allegedly Over, Questions Are Not

The U.S. Centers for Disease Control and Prevention (CDC) alleges that the Salmonella outbreak is over. There were no recorded cases after August 11th, which means that the bacteria's spread has...

We Teach You How To Swat A Fly

We Teach You How To Swat A Fly

Scientists at the California Institute of Technology (Caltech) believe they solved the puzzle regarding the fly’s ability to leap before being hit. Led by Michael Dickinson, the U.S. researchers...

Bristol And Pfizer Won’t Seek Approval For Blood Clotting Drug

Bristol-Myers Squibb Co and its partner Pfizer Inc said Tuesday that their apixaban anticoagulant didn’t comply with the requirements regarding its main objective.Moreover, the global pharmaceutical...

California Health Care Workers Launch Strike to Protect Their Rights

Hundreds of unsatisfied healthcare workers at five hospitals through the state, including in Daly City, San Jose, Moss Beach and Gilroy, launched a 24-hour strike on Thursday against the...

dotclear
Latest videos in Health
Olympic Swimmer Has Cancer...
Dorm Room Bedbugs
Dogs Can Smell Skin Cancer?
HealthWatch
Allergy Attacks At School

dotclear
Health You are here: Health
» Science   » Health   
E-mail To A Friend Print RSS Text size: Decrease font size Increase font size
dotclear
dotclear
dotclear
Most Popular in Health
Update: Incense Burning Might Lead To CancerUpdate: Incense Burning Might Lead To Cancer

» read full story
dotclear

Interested In This Topic?

News Alert will keep you informed. Find out more.
dotclear
Photos Gallery
dotclear
Today's Latest News
The West Nile Virus, Public Enemy Number 1The West Nile Virus, Public Enemy Number 1

» read full story
dotclear